(Reuters) - Antisoma said on Thursday that new Phase II data showed ASA404 did not increase the median time to tumor progression when added to chemotherapy.
More women died in the ASA404 arm of the study than in the control group but the majority in both were still alive after one year, so no median survival values were determined.
Read more at Reuters.com Hot Stocks News
More women died in the ASA404 arm of the study than in the control group but the majority in both were still alive after one year, so no median survival values were determined.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment